|
KMID : 1100120220290040217
|
|
대한골대사학회지
2022 Volume.29 No. 4 p.217 ~ p.223
|
|
|
The Role of Bisphosphonates Prior to Denosumab Treatment on Rebound Fractures: A Mini Review
|
|
Inojosa Arthur Costa
Mendes Lais
Bandeira Leonardo
Bandeira Francisco
|
|
|
Abstract
|
|
|
|
Denosumab is a potent anti-resorptive medication used to treat patients at high risk for osteoporosis; however, its beneficial effects on the skeletal system are quickly reversed after discontinuation. In contrast, bisphosphonates (BPs) are anti-resorptive agents with residual effects on the bone matrix; thus, these are capable of preserving bone mass for a long time. Therefore, subsequent anti-resorptive treatment with BPs is mandatory to prevent rebound fractures. Furthermore, BP administration before denosumab treatment appears to be a reasonable strategy for reducing hyperactivation of bone remodeling. In this review, we summarize the effects of BP administration before denosumab treatment in preventing rebound fractures after denosumab discontinuation.
|
|
|
KEYWORD
|
|
|
Bisphosphonates, Denosumab, Fractures, bone, Osteoporosis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|